Logo

Clarification: Jan 13, 2005

Jan 13, 2005
Premium

In Pharmacogenomics Reporter issue 1/6/2005, the article “FDA Clears Half of AmpliChip for Sale As an IVD; Rival Dx Shops Bear Down” characterized Paul Billings of LabCorp as saying “evidence, patient requests, quality, and liability concerns,” contributed to slow early P450 test demand. The text should have characterized these factors only as affecting demand.

Filed under

Diagnostics
Breaking News
The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.